CV Sciences (OTCMKTS:CVSI) Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research upgraded shares of CV Sciences (OTCMKTS:CVSI) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, Zacks.com reports. They currently have $1.00 target price on the stock.
According to Zacks, “CV Sciences Inc. is a life science company. Its operating segment consists of specialty pharmaceuticals and consumer products. Specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol across several therapeutic areas. Consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products. It operates primarily in San Diego, California and Las Vegas, Nevada. CV Sciences Inc. is based in Las Vegas, United States. “
Several other research firms also recently commented on CVSI. ValuEngine downgraded shares of CV Sciences from a buy rating to a hold rating in a report on Saturday, February 1st. Cantor Fitzgerald initiated coverage on shares of CV Sciences in a report on Thursday, November 7th. They issued an overweight rating on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. CV Sciences currently has an average rating of Buy and an average target price of $5.75.
CV Sciences Company Profile
CV Sciences, Inc operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.
Recommended Story: P/E Growth (PEG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.